Related Experiment Video
Updated: Jun 9, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Cystic Fibrosis-Asthma Overlap Syndrome: Current Understanding and Future Directions
Irina Miralda1, Daniel S Aridgides2, Hazel Ozuna1
1Department of Pediatrics, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA.
Background:
Cystic fibrosis-asthmaoverlap syndrome (CFAOS) has high incidence in people with CF (pwCF) yet remains poorly defined, hindering both diagnosis and treatment. Asthmatic type2 (T2) inflammation (eosinophilia, elevated IgE, and increased IL-4/IL-5/IL-13), identifies an endo type within the CF community with accelerated disease progression and increased mortality. However, diagnostic criteria for asthma in the general population are less useful inpwCF due to overlapping phenotypes generated by chronic inflammation and structural lung disease. Therapeutically, the lack of standardized CFAOS diagnostic criteria has led to the heterogenous use of asthma-directed therapies, with inconsistent benefits.
Objective:
This review summarizes current CFAOS diagnostic and therapeutic approaches, explores the role of T2 inflammation in CFpathophysiology, and identifies critical research priorities for defining clinically meaningful subgroups and optimizing treatment strategies.
Methods:
We conducted a comprehensive literature search of peer-reviewed publications on the PubMed database related to asthma diagnosis and treatment, markers of T2 inflammation in samples from pwCF, CFAOS.
Results:
Emerging evidence suggests that CFTR deficiency in immune cells enhances their responsiveness to T2 stimuli. Combined with individual genetic and environmental contexts that also drive T2 inflammation,this could explain the higher incidence of asthma in pwCF. There is a critical need to better identify asthma in pwCF and transition to using bio markers to select those who would benefit from targeted asthma biologic therapies.
More Related Videos
06:57The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma I: Introduction
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: